Angiotensin-converting enzyme inhibitors, angiotensin ii receptor blockers and diabetes: A meta-analysis of placebo-controlled clinical trials

Giuliano Tocci, Francesco Paneni, Francesca Palano, Sebastiano Sciarretta, Andrea Ferrucci, Theodore Kurtz, Giuseppe Mancia, Massimo Volpe

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

BackgroundTo determine whether the administration of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) on top of standard cardiovascular (CV) therapies may reduce the incidence of new onset diabetes (NOD) in placebo-controlled clinical trials. The effects of these drugs on CV and non-CV mortality were also tested.MethodsWe performed a meta-analysis of all randomized clinical trials (11 trials, n = 84,363 patients, aged 64.2± 5.86 years), published until 14 March 2010, in which ACE inhibitors or ARBs were compared with placebo and NOD incidence, CV, and non-CV mortality were reported.ResultsOver an average follow-up of 4.0 ±1.0 years, there were 1,284/15,142 (8.5%) cases of NOD in active-treated and 1,411/15,130 (9.3%) cases in placebo-treated patients in the ACE inhibitor trials, and 2,330/18,756 (12.4%) cases in active-treated and 2,669/18,800 (14.2%) cases in placebo-treated patients in the ARB trials. Overall, active therapy reduced NOD compared to placebo (odds ratio (OR) 95%, confidence interval (CI): 0.8 (0.8-0.9); P

Original languageEnglish
Pages (from-to)582-590
Number of pages9
JournalAmerican Journal of Hypertension
Volume24
Issue number5
DOIs
Publication statusPublished - May 2011

Fingerprint

Angiotensin Receptor Antagonists
Controlled Clinical Trials
Angiotensin-Converting Enzyme Inhibitors
Meta-Analysis
Placebos
Cardiovascular Agents
Mortality
Incidence
Randomized Controlled Trials
Odds Ratio
Confidence Intervals
Therapeutics

Keywords

  • angiotensin II receptor blockers
  • angiotensin-converting enzyme inhibitors
  • blood pressure
  • cardiovascular mortality
  • hypertension
  • meta-analysis
  • new onset diabetes mellitus
  • non-cardiovascular mortality
  • randomized clinical trials

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Angiotensin-converting enzyme inhibitors, angiotensin ii receptor blockers and diabetes : A meta-analysis of placebo-controlled clinical trials. / Tocci, Giuliano; Paneni, Francesco; Palano, Francesca; Sciarretta, Sebastiano; Ferrucci, Andrea; Kurtz, Theodore; Mancia, Giuseppe; Volpe, Massimo.

In: American Journal of Hypertension, Vol. 24, No. 5, 05.2011, p. 582-590.

Research output: Contribution to journalArticle

@article{feee6de532674b26a4775cc9b02fb1dc,
title = "Angiotensin-converting enzyme inhibitors, angiotensin ii receptor blockers and diabetes: A meta-analysis of placebo-controlled clinical trials",
abstract = "BackgroundTo determine whether the administration of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) on top of standard cardiovascular (CV) therapies may reduce the incidence of new onset diabetes (NOD) in placebo-controlled clinical trials. The effects of these drugs on CV and non-CV mortality were also tested.MethodsWe performed a meta-analysis of all randomized clinical trials (11 trials, n = 84,363 patients, aged 64.2± 5.86 years), published until 14 March 2010, in which ACE inhibitors or ARBs were compared with placebo and NOD incidence, CV, and non-CV mortality were reported.ResultsOver an average follow-up of 4.0 ±1.0 years, there were 1,284/15,142 (8.5{\%}) cases of NOD in active-treated and 1,411/15,130 (9.3{\%}) cases in placebo-treated patients in the ACE inhibitor trials, and 2,330/18,756 (12.4{\%}) cases in active-treated and 2,669/18,800 (14.2{\%}) cases in placebo-treated patients in the ARB trials. Overall, active therapy reduced NOD compared to placebo (odds ratio (OR) 95{\%}, confidence interval (CI): 0.8 (0.8-0.9); P",
keywords = "angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors, blood pressure, cardiovascular mortality, hypertension, meta-analysis, new onset diabetes mellitus, non-cardiovascular mortality, randomized clinical trials",
author = "Giuliano Tocci and Francesco Paneni and Francesca Palano and Sebastiano Sciarretta and Andrea Ferrucci and Theodore Kurtz and Giuseppe Mancia and Massimo Volpe",
year = "2011",
month = "5",
doi = "10.1038/ajh.2011.8",
language = "English",
volume = "24",
pages = "582--590",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Angiotensin-converting enzyme inhibitors, angiotensin ii receptor blockers and diabetes

T2 - A meta-analysis of placebo-controlled clinical trials

AU - Tocci, Giuliano

AU - Paneni, Francesco

AU - Palano, Francesca

AU - Sciarretta, Sebastiano

AU - Ferrucci, Andrea

AU - Kurtz, Theodore

AU - Mancia, Giuseppe

AU - Volpe, Massimo

PY - 2011/5

Y1 - 2011/5

N2 - BackgroundTo determine whether the administration of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) on top of standard cardiovascular (CV) therapies may reduce the incidence of new onset diabetes (NOD) in placebo-controlled clinical trials. The effects of these drugs on CV and non-CV mortality were also tested.MethodsWe performed a meta-analysis of all randomized clinical trials (11 trials, n = 84,363 patients, aged 64.2± 5.86 years), published until 14 March 2010, in which ACE inhibitors or ARBs were compared with placebo and NOD incidence, CV, and non-CV mortality were reported.ResultsOver an average follow-up of 4.0 ±1.0 years, there were 1,284/15,142 (8.5%) cases of NOD in active-treated and 1,411/15,130 (9.3%) cases in placebo-treated patients in the ACE inhibitor trials, and 2,330/18,756 (12.4%) cases in active-treated and 2,669/18,800 (14.2%) cases in placebo-treated patients in the ARB trials. Overall, active therapy reduced NOD compared to placebo (odds ratio (OR) 95%, confidence interval (CI): 0.8 (0.8-0.9); P

AB - BackgroundTo determine whether the administration of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) on top of standard cardiovascular (CV) therapies may reduce the incidence of new onset diabetes (NOD) in placebo-controlled clinical trials. The effects of these drugs on CV and non-CV mortality were also tested.MethodsWe performed a meta-analysis of all randomized clinical trials (11 trials, n = 84,363 patients, aged 64.2± 5.86 years), published until 14 March 2010, in which ACE inhibitors or ARBs were compared with placebo and NOD incidence, CV, and non-CV mortality were reported.ResultsOver an average follow-up of 4.0 ±1.0 years, there were 1,284/15,142 (8.5%) cases of NOD in active-treated and 1,411/15,130 (9.3%) cases in placebo-treated patients in the ACE inhibitor trials, and 2,330/18,756 (12.4%) cases in active-treated and 2,669/18,800 (14.2%) cases in placebo-treated patients in the ARB trials. Overall, active therapy reduced NOD compared to placebo (odds ratio (OR) 95%, confidence interval (CI): 0.8 (0.8-0.9); P

KW - angiotensin II receptor blockers

KW - angiotensin-converting enzyme inhibitors

KW - blood pressure

KW - cardiovascular mortality

KW - hypertension

KW - meta-analysis

KW - new onset diabetes mellitus

KW - non-cardiovascular mortality

KW - randomized clinical trials

UR - http://www.scopus.com/inward/record.url?scp=79954933210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954933210&partnerID=8YFLogxK

U2 - 10.1038/ajh.2011.8

DO - 10.1038/ajh.2011.8

M3 - Article

C2 - 21331058

AN - SCOPUS:79954933210

VL - 24

SP - 582

EP - 590

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 5

ER -